Literature DB >> 31049983

Implementation of a Stewardship Initiative on Respiratory Viral PCR-based Antibiotic Deescalation.

Pavithra Srinivas1,2, Kaitlyn R Rivard1, Andrea M Pallotta1,3, Vasilios Athans1, Kristin Martinez4, Samantha Loutzenheiser3, Simon W Lam1, Gary W Procop5, Sandra S Richter5, Elizabeth A Neuner1.   

Abstract

OBJECTIVE: Respiratory viral polymerase chain reaction (RV PCR) tests assist in rapidly identifying viral pathogens and differentiating viral versus bacterial causes of pneumonia. Studies evaluating the use of RV PCR tests on antibiotic use in adults have demonstrated mixed results. We implemented an antimicrobial stewardship (ASP) intervention for patients with a positive RV PCR test result who were receiving broad-spectrum antibiotics and aimed to assess the impact on antibiotic usage.
METHODS: Retrospective quasi-experimental study of adult hospitalized patients comparing time to antibiotic deescalation, duration of antibiotic therapy, and antiviral use preintervention (January-March 2016) and postintervention (January-March 2017).
RESULTS: Of 172 ASP alerts reviewed, 55 (32%) were considered actionable. Of these, 47% of interventions were accepted. No significant difference was observed in median time to antibiotic deescalation (pre: 2.7 days vs post: 2.3 days, p=0.88). Time to discontinuation of antimicrobial therapy pre- and postintervention was reduced from 4 to 1.9 days (p=0.057) for piperacillin-tazobactam, from 2.7 to 1.8 days (p=0.75) for ceftriaxone, and from 3.6 to 2 days (p=0.4) for levofloxacin, respectively. Time to initiation of oseltamivir for influenza was significantly shorter in the postintervention group (pre: 11.3 hrs vs post: 3.6 hrs, p=0.02).
CONCLUSION: A third of patients receiving broad-spectrum antibiotics with a positive RV PCR had an opportunity for antimicrobial optimization, although this did not translate into a significant impact on the time to antibiotic deescalation or overall antibiotic use. Combination of RV PCR results with biomarkers to rule out bacterial coinfections and chest radiographic findings may help enhance the likelihood of accepted antibiotic deescalation recommendations and represents an area of future research.
© 2019 Pharmacotherapy Publications, Inc.

Entities:  

Keywords:  antimicrobial stewardship; respiratory virus; viral pneumonia

Mesh:

Substances:

Year:  2019        PMID: 31049983     DOI: 10.1002/phar.2268

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN: 0277-0008            Impact factor:   4.705


  6 in total

Review 1.  Syndromic Multiplex Polymerase Chain Reaction (mPCR) Testing and Antimicrobial Stewardship: Current Practice and Future Directions.

Authors:  Theodore S Rader; Michael P Stevens; Gonzalo Bearman
Journal:  Curr Infect Dis Rep       Date:  2021-02-26       Impact factor: 3.725

Review 2.  Antimicrobial Stewardship Interventions to Combat Antibiotic Resistance: an Update on Targeted Strategies.

Authors:  Kelli A Cole; Kaitlyn R Rivard; Lisa E Dumkow
Journal:  Curr Infect Dis Rep       Date:  2019-08-31       Impact factor: 3.663

Review 3.  Appropriate Use and Future Directions of Molecular Diagnostic Testing.

Authors:  Erin H Graf; Preeti Pancholi
Journal:  Curr Infect Dis Rep       Date:  2020-02-06       Impact factor: 3.725

4.  Use of Procalcitonin and a Respiratory Polymerase Chain Reaction Panel to Reduce Antibiotic Use via an Electronic Medical Record Alert.

Authors:  Tony Moradi; Nicholas Bennett; Shelby Shemanski; Kevin Kennedy; Andrew Schlachter; Sarah Boyd
Journal:  Clin Infect Dis       Date:  2020-10-23       Impact factor: 9.079

Review 5.  Impact of multiplexed respiratory viral panels on infection control measures and antimicrobial stewardship: a review of the literature.

Authors:  Jense Wils; Veroniek Saegeman; Annette Schuermans
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2021-11-20       Impact factor: 3.267

Review 6.  Value of syndromic panels in the management of severe community-acquired pneumonia.

Authors:  A Burillo; F J Candel; A Canut-Blasco
Journal:  Rev Esp Quimioter       Date:  2022-04-22       Impact factor: 2.515

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.